Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Rangaswamy Govindarajan

Concepts (128)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colonic Neoplasms
3
2016
162
0.930
Why?
Anus Neoplasms
1
2018
30
0.730
Why?
Bone Marrow Neoplasms
1
2015
15
0.610
Why?
Embolism
1
2015
26
0.610
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2020
1020
0.600
Why?
African Americans
2
2016
719
0.590
Why?
Gene Regulatory Networks
1
2016
124
0.580
Why?
Tumor Lysis Syndrome
1
2014
7
0.570
Why?
Carcinoma, Squamous Cell
1
2018
391
0.550
Why?
Neoplasm Recurrence, Local
1
2018
587
0.540
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2014
75
0.540
Why?
Pyrazoles
1
2014
119
0.530
Why?
Pyrimidines
1
2014
198
0.500
Why?
Biliary Tract Diseases
1
2012
12
0.490
Why?
Actinomycosis
1
2012
10
0.490
Why?
Salvage Therapy
1
2013
141
0.490
Why?
Angiogenesis Inhibitors
2
2006
214
0.490
Why?
Bile Duct Neoplasms
1
2012
30
0.480
Why?
Stomach Neoplasms
1
2015
168
0.480
Why?
Clinical Trials as Topic
5
2019
501
0.480
Why?
Benzenesulfonates
2
2011
12
0.440
Why?
Prognosis
6
2019
2094
0.430
Why?
Carcinoma, Hepatocellular
1
2013
189
0.430
Why?
Gene Expression Profiling
1
2016
1117
0.420
Why?
Middle Aged
12
2020
13540
0.400
Why?
Stroke
1
2015
525
0.400
Why?
Pyridines
2
2011
141
0.400
Why?
Colorectal Neoplasms
2
2003
222
0.400
Why?
Liver Neoplasms
1
2013
328
0.390
Why?
Drug Industry
1
2007
40
0.330
Why?
Hypertensive Encephalopathy
1
2006
4
0.330
Why?
raf Kinases
1
2006
5
0.330
Why?
Heparin
1
2007
99
0.330
Why?
Communication Barriers
1
2007
41
0.330
Why?
Thrombocytopenia
1
2007
92
0.330
Why?
Aged, 80 and over
6
2018
3604
0.320
Why?
Thiazolidinediones
1
2007
104
0.320
Why?
Aged
9
2020
10361
0.280
Why?
Anticoagulants
1
2007
268
0.270
Why?
Thrombosis
1
2007
261
0.270
Why?
Skin
1
2007
438
0.270
Why?
Adult
9
2020
14221
0.260
Why?
Enzyme Inhibitors
1
2006
450
0.260
Why?
Prostatic Neoplasms
1
2007
407
0.250
Why?
Female
11
2020
28639
0.250
Why?
Survival Rate
2
2018
1004
0.250
Why?
Humans
16
2020
52189
0.240
Why?
Camptothecin
1
2002
18
0.240
Why?
Follow-Up Studies
3
2019
2412
0.230
Why?
Diabetes Mellitus, Type 2
1
2007
448
0.230
Why?
Lung Neoplasms
1
2007
594
0.220
Why?
Antineoplastic Agents, Phytogenic
1
2002
90
0.220
Why?
Oximes
1
2020
11
0.220
Why?
Male
10
2020
27947
0.220
Why?
Pyrimidinones
1
2020
17
0.220
Why?
Pyridones
1
2020
43
0.210
Why?
Thalidomide
1
2002
405
0.190
Why?
Imidazoles
1
2020
153
0.190
Why?
Cholangiocarcinoma
2
2011
28
0.190
Why?
Protein Kinase Inhibitors
1
2020
214
0.180
Why?
Survival Analysis
3
2020
797
0.170
Why?
Melanoma
1
2020
314
0.160
Why?
Antineoplastic Agents
2
2019
1278
0.160
Why?
Neoplasm Staging
2
2013
801
0.150
Why?
Combined Modality Therapy
1
2018
704
0.150
Why?
Severity of Illness Index
1
2019
1106
0.140
Why?
Gene Amplification
1
2015
59
0.140
Why?
Polycomb Repressive Complex 2
1
2015
50
0.140
Why?
Adenine
1
2014
46
0.140
Why?
Genes, myc
1
2015
48
0.140
Why?
Retrospective Studies
3
2018
5933
0.140
Why?
Skin Neoplasms
1
2020
538
0.140
Why?
Antibodies, Monoclonal
1
2019
559
0.140
Why?
Piperidines
1
2014
103
0.130
Why?
United States
3
2019
5046
0.130
Why?
Registries
3
2007
541
0.130
Why?
Gene Deletion
1
2015
289
0.130
Why?
Quinazolines
1
2013
38
0.130
Why?
Leukemia, Myeloid, Acute
1
2015
178
0.130
Why?
Actinomyces
1
2012
9
0.120
Why?
Treatment Outcome
4
2020
5572
0.120
Why?
Endoscopy, Gastrointestinal
1
2012
74
0.120
Why?
Gallbladder Neoplasms
1
2011
8
0.110
Why?
Comorbidity
2
2019
695
0.110
Why?
Gene Expression Regulation, Neoplastic
1
2016
891
0.110
Why?
Phenylurea Compounds
2
2011
13
0.110
Why?
Antibodies, Monoclonal, Humanized
1
2013
228
0.110
Why?
Niacinamide
2
2011
24
0.110
Why?
Incidence
2
2019
1088
0.100
Why?
Neoplasms
1
2019
1240
0.100
Why?
Necrosis
1
2007
197
0.080
Why?
Causality
1
2007
50
0.080
Why?
Drugs, Investigational
1
2007
20
0.080
Why?
Hospitals, University
1
2007
95
0.080
Why?
Confidence Intervals
1
2007
178
0.080
Why?
United States Food and Drug Administration
1
2007
96
0.080
Why?
Probability
1
2007
187
0.080
Why?
Neoplasm Metastasis
2
2011
262
0.080
Why?
Age Distribution
1
2007
208
0.080
Why?
Tomography, X-Ray Computed
1
2012
1272
0.080
Why?
Anti-Bacterial Agents
1
2012
782
0.080
Why?
Medical Oncology
1
2007
106
0.080
Why?
Syndrome
1
2006
258
0.080
Why?
Patient Selection
1
2007
294
0.070
Why?
Publication Bias
1
2005
15
0.070
Why?
Editorial Policies
1
2005
13
0.070
Why?
Periodicals as Topic
1
2005
69
0.070
Why?
Dose-Response Relationship, Drug
1
2007
1559
0.060
Why?
Risk Assessment
1
2007
1408
0.060
Why?
MAP Kinase Kinase Kinases
1
2020
18
0.050
Why?
Socioeconomic Factors
1
2003
636
0.050
Why?
Proto-Oncogene Proteins B-raf
1
2020
89
0.050
Why?
Mutation, Missense
1
2020
115
0.050
Why?
Trisaccharides
1
2019
1
0.050
Why?
Premedication
1
2019
19
0.050
Why?
Drug Administration Schedule
1
2020
426
0.050
Why?
Administration, Oral
1
2020
473
0.050
Why?
Infusions, Intravenous
1
2019
245
0.050
Why?
Antibodies
1
2019
172
0.050
Why?
Magnetic Resonance Imaging
1
2006
1667
0.050
Why?
Health Services Accessibility
1
2003
436
0.040
Why?
Disease Management
1
2019
199
0.040
Why?
Arkansas
1
2003
2178
0.040
Why?
Adolescent
1
2007
6805
0.040
Why?
In Situ Hybridization, Fluorescence
1
2015
274
0.030
Why?
Polymorphism, Single Nucleotide
1
2015
567
0.030
Why?
Young Adult
1
2020
4239
0.030
Why?
Disease-Free Survival
1
2011
520
0.030
Why?
Govindarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description